Mucin Binding Lectin Imaging Agents for Colonic Polyp Imaging
Description of Invention:
Available for licensing and commercial development is an imaging agent specific for colonic polyps that overexpress glycoprotein alpha-L-fucose containing mucins. Colon cancer is the second leading cause of cancer related deaths in the United States. The legume protein Ulex europaeus agglutinin I (UEA-1) has shown high specificity to alpha-L-fucose glycoproteins. Colonic mucosal neoplasia and/or polyps with high surface expression of alpha-L-fucosyl terminal residues can be specifically targeted with UEA-1 contrast agents. In one example, a computer tomography (CT) agent made from Iodine-127 (127I) labeled UEA-1 (I-UEA-1) and encapsulated into polymeric liposome nanoparticles was used to image murine colonic polyps. Ideally, the inventors envision a contrast agent that can be administered orally (e.g., liquid or pill form) and that would eliminate a patient’s need to drink harsh enema/contrast solutions prior to CT imaging.
Applications:
Colon cancer
Cancer imaging
Contrast agents
CT colonography
Inventors: Ronald M. Summers (CC) Jianwu Xie (CC) Celeste Roney (CC)
Patent Status:
DHHS Reference No. E-254-2007/0 --
U.S. Provisional Application No. 61/064,086 filed 15 Feb 2008
C Roney et al. Glycoprotein expression by adenomatous polyps of the colon. Proc. SPIE, Vol 6916, 691601 (2008); Published online 12 March 2008, doi:10.1117/12.769224.
SD O’Connor et al. Oral contrast adherence to polyps on CT colonography. J Comput Assist Tomogr. 2006 Jan-Feb;30(1):51-57. [PubMed abs]
For Additional Information Please Contact: Michael Shmilovich J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5019
Email: shmilovm@mail.nih.gov
Fax: (301) 402-0220
